Oncology Central

Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?


The detection of multiple primary cancers in the same patient has increased in frequency during the last decades. Those diagnosed cancers are either synchronous, detected at the same time or metachronous, occurring after a period of time following the first cancer. A review of the literature of nearly one million cancer patients concluded that the prevalence of multiple primary malignant cancers was between 0.73 and 11.7% [1]. Overall, cancer survivors had a 14% higher risk of developing a new malignancy than would have been expected in the general population [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.